Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Adverum Biotechnologies (ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET
- Chardan's 8th Annual Genetic Medicines Conference on October 1st at 8:00 a.m. ET
- UBS Virtual Ophthalmology Day on October 2nd at 10:30 a.m. ET
On-demand webcasts of these presentations will be available in the Investors section of Adverum's website under Events and Presentations. Replays will be accessible for at least 30 days following each event.
Adverum Biotechnologies (ADVM), una società in fase Clinica focalizzata sulla terapia genica per le malattie oculari, ha annunciato la sua partecipazione a tre prossimi eventi di conferenza per investitori:
- 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright il 10 settembre alle 15:30 ET
- 8ª Conferenza Annuale sui Medicinali Genetici di Chardan il 1° ottobre alle 8:00 ET
- Giornata Virtuale di Oftalmologia UBS il 2 ottobre alle 10:30 ET
Le registrazioni on-demand di queste presentazioni saranno disponibili nella sezione Investitori del sito web di Adverum sotto Eventi e Presentazioni. Le riproduzioni saranno accessibili per almeno 30 giorni dopo ciascun evento.
Adverum Biotechnologies (ADVM), una empresa en etapa clínica centrada en la terapia génica para enfermedades oculares, ha anunciado su participación en tres próximas conferencias para inversores:
- 26ª Conferencia Anual Global de Inversiones H.C. Wainwright el 10 de septiembre a las 3:30 p.m. ET
- 8ª Conferencia Anual de Medicinas Genéticas de Chardan el 1 de octubre a las 8:00 a.m. ET
- Día Virtual de Oftalmología de UBS el 2 de octubre a las 10:30 a.m. ET
Las retransmisiones a la carta de estas presentaciones estarán disponibles en la sección de Inversores del sitio web de Adverum bajo Eventos y Presentaciones. Las repeticiones estarán accesibles durante al menos 30 días después de cada evento.
Adverum Biotechnologies (ADVM), 안질환을 위한 유전자 치료에 중점을 둔 임상 단계 회사가 세 개의 투자자 회의에 참여한다고 발표했습니다:
- 9월 10일 오후 3시 30분 ET에 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의
- 10월 1일 오전 8시 ET에 열리는 Chardan 제8회 연례 유전 치료 회의
- 10월 2일 오전 10시 30분 ET에 열리는 UBS 가상 안과의 날
이 발표의 온디맨드 웹캐스트는 Adverum 웹사이트의 투자자 섹션에서 이벤트 및 발표 아래에서 확인할 수 있습니다. 각 이벤트 후 최소 30일 동안 재생할 수 있습니다.
Adverum Biotechnologies (ADVM), une entreprise en phase clinique axée sur la thérapie génique pour les maladies oculaires, a annoncé sa participation à trois prochaines conférences pour investisseurs :
- 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 10 septembre à 15h30 ET
- 8e Conférence Annuelle sur les Médicaments Génétiques de Chardan le 1er octobre à 8h00 ET
- Journée Virtuelle d'Ophthalmologie UBS le 2 octobre à 10h30 ET
Les webinaires à la demande de ces présentations seront disponibles dans la section Investisseurs du site web d'Adverum sous Événements et Présentations. Les rediffusions seront accessibles pendant au moins 30 jours après chaque événement.
Adverum Biotechnologies (ADVM), ein Unternehmen in der klinischen Phase, das sich auf Gentherapie bei Augenerkrankungen spezialisiert hat, gab seine Teilnahme an drei bevorstehenden Investorenkonferenzen bekannt:
- 26. jährliche globale Investorenkonferenz von H.C. Wainwright am 10. September um 15:30 Uhr ET
- 8. jährliche Konferenz für genetische Therapien von Chardan am 1. Oktober um 8:00 Uhr ET
- UBS virtueller Augenheiltag am 2. Oktober um 10:30 Uhr ET
On-Demand-Webcasts dieser Präsentationen werden im Bereich Investoren auf der Website von Adverum unter Ereignisse und Präsentationen verfügbar sein. Wiedergaben werden mindestens 30 Tage nach jeder Veranstaltung zugänglich sein.
- None.
- None.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10th at 3:30 p.m. ET.
- Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1st at 8:00 a.m. E.T.
- UBS Virtual Ophthalmology Day on Wednesday, October 2nd at 10:30 a.m. ET.
The on-demand webcasts may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of each webcast will be available on the website for at least 30 days following the events.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
What investor conferences is Adverum Biotechnologies (ADVM) attending in Fall 2024?
When is Adverum Biotechnologies (ADVM) presenting at the H.C. Wainwright Conference?
How can investors access Adverum Biotechnologies' (ADVM) conference presentations?
What is the focus of Adverum Biotechnologies' (ADVM) research?
